MBIO - Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies
- Mustang Bio remains underfollowed despite having several therapies that have the potential to be major breakthroughs in some of the most notorious and hard-to-treat diseases.
- MBIO's share price is near the 52-week lows despite the company completing milestones and a few bullish catalysts ahead. Several programs are moving closer to their pivotal studies.
- I review some of the recent updates and discuss how they bolster my bullish outlook. In addition, I point out some of my leading downside risks.
- I take a look at charts to map out my next MBIO buy.
For further details see:
Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies